Heart rhythm risks in ATTR amyloidosis patients on tafamidis under scrutiny

NCT ID NCT06251778

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 200 adults with ATTRwt amyloidosis who are taking tafamidis to see how often they develop heart rhythm problems that need a pacemaker or defibrillator. Researchers will also track changes in diuretic use. Participants are checked every six months as part of routine care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tafamidis

What this could lead to

If successful, this study could improve how doctors monitor and manage heart rhythm problems in people with ATTR amyloidosis.

What could go wrong

This is an observational study, not a treatment trial. It may not lead to new therapies, and results depend on routine care, which varies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Amyloid Neuropathies, Familial amyloidosis wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fondazione IRCCS Policlinico San Matteo

    RECRUITING

    Pavia, 27100, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••